Please ensure Javascript is enabled for purposes of website accessibility

This Pet Stock Just Bought an Animal Health Business for $7.6 Billion

By Luis Sanchez CFA – Sep 2, 2020 at 8:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The acquisition of Bayer Animal Health establishes Elanco as the second-largest animal health company in the world.

Based in Indiana, Elanco Animal Health (ELAN -1.34%) develops products and services that treat diseases in pets and commercial animals around the world. Just two short years after being spun off from Eli Lilly, Elanco has taken a bold step by acquiring Bayer Animal Health in a $7.6 billion move that establishes it as the second-largest animal health company in the world by revenue (behind Zoetis).

A $7.6 billion animal-health merger

The deal was announced in August 2019 and was financed with $5.2 billion in cash and 72.9 million shares of Elanco. Management believes Bayer will help it strengthen its focus on the connections between pet health and farm animal health, as well as providing new research and development capabilities that will help expand the portfolio of pet and farm products and generate future cash flow growth.

The deal will triple Elanco's international footprint, and that greater scale should help the combined company cut better distribution agreements and allow it to reach more customers.

Finally, adding Bayer increases Elanco's exposure to the pet health market to 50% of its total revenue. While both companies serve pets and livestock alike, the pet health market is more attractive because it is higher-margin and is growing faster. If investors see this acquisition as making Elanco into more of a play on the pet-health market, its valuation multiple could rise.

Dog on exam table with pink tape on paw at veterinary office

Image Source: Getty Images.

Financial outlook for the combined company

The negative effects of COVID-19 have made 2020 a tough year for the animal health market. The coronavirus outbreak disrupted the food supply chain, leading farmers to reduce spending on livestock due to a lack of demand from restaurants and meat processing facilities. However, the pet health market has been relatively stable. The net impact for Elanco has been a 25% decrease in revenue compared to 2019.

Management believes the acquisition of Bayer will result in improved margins, predicting that gross margin will rise to 60% by 2022 from 52% in 2019. The increase will be driven by $300 million in cost synergies, increased sales of higher-margin pet products, and operating leverage from revenue growth, which management believes will also accelerate at a rate in the mid-single digits.

Besides a greater focus on the pet market, the rise of e-commerce in selling pet health products should boost Elanco's returns. Selling online will provide Elanco better access to the nearly one-third of pet owners who do not regularly visit a veterinarian. Finally, the combined R&D resources of Elanco and Bayer are expected to result in an increased pace of product development, which should result in more products to sell.

Overall, a combined Elanco and Bayer should be able to produce faster growth and higher margins, which should accrue to shareholder value. This could make Elanco an ideal animal healthcare stock to own in the coming years.

Luis Sanchez CFA owns shares of Zoetis. The Motley Fool owns shares of Zoetis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Elanco Animal Health Incorporated Stock Quote
Elanco Animal Health Incorporated
$13.22 (-1.34%) $0.18
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$311.46 (0.19%) $0.59
Zoetis Inc. Stock Quote
Zoetis Inc.
$150.05 (0.40%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.